Grant Life Sciences gets IP boost for cervical cancer blood test
This article was originally published in Clinica
Executive Summary
Moving forward with development plans for its cervical cancer blood test, US firm Grant Life Sciences (GLS) has secured key intellectual property covering the product's fundamental technology. The test, which is currently undergoing validation studies, promises to offer a more reliable alternative to the Pap smear.